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Abstract: The complexity of human tissue fluid precludes timely identification of cancer biomarkers
by immunoassay or mass spectrometry. An increasingly attractive strategy is to primarily enrich
extracellular vesicles (EVs) released from cancer cells in an accelerated manner compared to normal
cells. The Vn96 peptide was herein employed to recover a subset of EVs released into the media
from cellular models of breast cancer. Vn96 has affinity for heat shock proteins (HSPs) decorating the
surface of EVs. Reflecting their cells of origin, cancer EVs displayed discrete differences from those of
normal phenotype. GELFrEE LC/MS identified an extensive proteome from all three sources of EVs,
the vast majority having been previously reported in the ExoCarta database. Pathway analysis of the
Vn96-affinity proteome unequivocally distinguished EVs from tumorigenic cell lines (SKBR3 and
MCF-7) relative to a non-tumorigenic source (MCF-10a), particularly with regard to altered metabolic
enzymes, signaling, and chaperone proteins. The protein data sets provide valuable information
from material shed by cultured cells. It is probable that a vast amount of biomarker identities may be
collected from established and primary cell cultures using the approaches described here.
Keywords: extracellular vesicles; breast cancer cell lines; Vn96; heat shock proteins;
glycolysis; GELFrEE
1. Introduction
According to the American Cancer Society, breast cancer remains the most commonly diagnosed
cancer among women in the United States, predicting over 250,000 new cases in 2017 and accounting
for 30% of all new cancer diagnoses [1]. Breast cancer further ranks second, behind lung cancer,
in terms of cancer cell death among women with >40,000 incidences in 2017. While five-year breast
cancer survival rates approach 100% in the case of localized tumors (stage 0 or I), the prognosis for
metastasized (stage IV) breast cancer is poor, with only 22% survival at 5 years [2]. Early detection of
breast cancer patients is thus crucial to improving recurrence-free survival and quality of life. Markers
that distinguish invasive breast cancer phenotypes are urgently required.
Conventional screening tools, such as self-examination, mammography, diagnostic imaging
(ultrasound, MRI), genetic screens (e.g., BRCA1), and tissue biopsies [3,4], collectively present vital
tools for breast cancer detection. As with all tests, limits in sensitivity and specificity will miss
some cancers (false-negatives); in other cases, abnormal findings associated with benign disease
(false positives) will direct between 55% and 75% of women into unnecessary and potentially toxic
chemotherapy [5–7]. The next generation of diagnostic and prognostic tests is continuously being
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sought. In particular, considerable effort is currently devoted to uncovering early molecular indicators
released into the blood by cancer cells [8]. To this end, both DNA from circulating tumor cells [9]
and microRNA released to plasma by cancer cells [10] have been reported as potential biomarkers.
Differentially expressed protein biomarkers have also been observed in plasma [11]. The presence of
high abundance background plasma proteins challenges the detection of low abundance proteins of
interest, pointing to a need for more selective and sensitive indicators of breast cancer.
Exosomes are a subclass of extracellular vesicles (EVs), constituting membranous spheroids
between 30 and 200 nM released from cells. Initially regarded as “cell dust”, EVs are now unequivocally
associated with various types of cancer, and carry specific profiles of proteins, nucleic acids, and lipids
that serve to transmit information to other cells. Once secreted by cells into the extracellular medium,
EVs retain features of the originating tissue environment [12]. EVs have also been shown to alter the
metabolic activity of neighboring cells [13], and thus, may have important functional implications
for tumor growth and differentiation. Not only are EVs with specific molecular payloads released
by cancer cells, but they are secreted in relative higher abundance. Hence, protein profiling of cancer
cell-derived exosomes has gained attention as a favorable source of protein biomarkers. Multiple
approaches are available to isolate exosomes from the bulk sample. The most common approach is
differential ultracentrifugation (UC); although laborious and producing a lower yield, UC remains the
“gold standard” in obtaining exosomes in high purity [14]. Whilst differential centrifugation remains
the laboratory method of choice [15], it is an inefficient and poorly reproducible tool that is unsuited
for handling even modest numbers of clinical samples [16,17]. Access to ultracentrifugation is also
limited in most clinical diagnostic laboratories, demanding robust alternative EV preparations for
future translational utility. Alternative approaches, including dialysis, size exclusion chromatography,
and polymer- or antibody-induced precipitation, are available [14].
In an alternative strategy, a synthetic peptide (Vn96) with high affinity for heat shock proteins
(HSPs) has recently been shown to selectively isolate EVs by co-precipitation [18]. Not surprisingly,
HSPs are overexpressed in cancer cells [19], where maintenance of protein homeostasis is at a premium,
due to hypoxia, low pH, and limited glucose availability. HSPs are also found in high abundance on
the plasma membrane surface of exosomes [20], thus, the Vn96 pulldown represents an ideal strategy
to enrich EVs shed from cancer cells. The Vn96 affinity peptide has previously been shown to recover
EV material from urine, plasma, as well as cancer cell lines [21–23].
In this study, we demonstrate for the first time the utility of Vn96 in isolating breast cancer EVs
for functional proteomic analysis of malignant phenotypes. We employ various breast cancer cells,
including the adenocarcinoma models SKBR3, an invasive HER2+ cell and MCF-7, a luminal A cell line
model. MCF-10a, a non-tumorigenic breast fibrocystic disease model, is also employed as a control.
In-depth proteome analysis by LC-MS/MS, following GELFrEE fractionation of exosomal proteins,
reveals numerous differentially expressed proteins, which readily distinguish the various cell lines.
The proteins convey unique profiles, particularly in terms of their metabolic and chaperone activity,
providing insight into the biological function of breast cancer-derived EVs and potentially pointing a
strategy to uncover protein biomarkers for early breast cancer detection.
2. Materials and Methods
2.1. Cell Culture and Sample Collection
Breast cancer cell lines (SKBR3, MCF-7), along with human breast epithelial cell MCF-10a,
were obtained from ATCC, and cultured according to recommended guidelines using CELLiNE
Integra bioreactor flasks (Sigma, Oakville, ON, Canada), which permits addition of fresh media to
layered and non-adhesive cells maintained on the opposing side of a 10 kDa membrane. The media
was supplemented with exosome-free fetal bovine serum (FBS), prepared by centrifugation of the
FBS (100,000g, 2 h, 4 ◦C) prior to use. CELLiNE media was harvested at 7–8 weeks, as optimized for
the collection of exosomes [24], and immediately combined with 5 µL protease cocktail inhibitor III
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per mL (Sigma). Remaining cells in the media were cleared by centrifugation (1000g, 10 min) and
microparticulate matter was further removed by centrifugation (17,000g, 5 min), followed by syringe
filtration through a 0.22 µmmembrane. Filtered solutions were stored at 4 ◦C.
2.2. Ultracentrifugation and Sucrose Density Gradient Fractionation
The filtered SKBR3 cellular media was subject to 45 min ultracentrifugation (200,000g, 4 ◦C).
The pellet was resuspended in 100 µL PBS, and overlaid onto a sucrose gradient (0.2–2.5 M), then spun
for an additional 1 h (100,000g). A total of 11 fractions were harvested, and the refractive index was
determined. Each density fraction was split in two equal portions of 250 µL, with one subject to Vn96
affinity pull-down while the other served as a control.
2.3. Vn96 Affinity Capture of EVs
Peptide Vn96 (New England Peptide, Gardener, MA, USA) was used to precipitate vesicular
material from the sucrose density fractions (Section 2.2), or from 1.9 mL of the microparticle-free
breast cancer cell media by adding 2.5 µL (or 10 µL for the cell culture media) of a 10 µg/µL stock
solution prepared in Extraction Buffer I of the subcellular proteome extraction kit (S-PEK, Millipore
Sigma), and also containing 0.04% sodium azide. The solution was briefly vortexed, and incubated
overnight at 4 ◦C. Complexedmaterial was pelleted by centrifugation (3000g, 5 min, room temperature).
The supernatant was removed, and the pelleted material was subject to two washes with 1.9 mL PBS
with 10 µL protease inhibitor, followed by centrifugation as above. The washed pelleted complex was
visible as a translucent straw-yellow residue.
2.4. EV Purity by Immunobloting and Transmission Electron Microscopy
Vn96-captured EVs were resuspended by vortex in SDS-PAGE sample buffer and heating at
95 ◦C for 5 min. Twenty microliter volumes were resolved on BioRad Criterion gels using XT-MES
or XT-MOPS electrophoresis running buffers (BioRad, Hercules, CA, USA). Resolved proteins were
transferred to either supported nitrocellulose (BioRad) or PVDF (Millipore) using standard procedures.
Total protein on blots was visualized with reversible stain using either the MemCode kit (PIERCE)
for nitrocellulose, or Red Alert Ponceau S (EMD Chemicals Gibbstown NJ). Membranes were blocked
in PBS containing 5% skimmed milk and 0.1% Tween-20 for 1 h, then incubated overnight at 4 ◦C
in primary antibody solutions (1:1000 dilution, prepared in blocking buffer with exception of 3%
milk powder). Four 10 min washes followed (blocking buffer without milk powder), then the blot
was incubated for 30 min at room temperature in secondary antibody (1:2000 dilution, HRP-labelled
antibody to the Ig consistent with primary antibody). All antibodies were obtained from Santa
Cruz Biotechnology. HRP signal was produced using SuperSignal West Dura substrate (Pierce).
The chemiluminescent image was captured using the ChemiGenius system (Syngene, Cambridge, UK).
For transmission electron microscopy, Vn96-captured EVs were prepared by fixation in aldehydes
and osmium tetroxide [21]. The fixed pellet was embedded in epoxy resin and prepared as 50 µm
sections. The sections were processed and examined by standard transmission electron microscopy.
2.5. Proteome Analysis
The Vn96 pellet was resuspended in 250 µL of SDS-PAGE sample buffer, supplemented to a
final concentration of 4 M urea and 25 mM TCEP reducing agent (Pierce). Following heating (95 ◦C,
10 min), 150 µL suspended protein solutions were respectively loaded onto each of three GELFrEE
cartridges (8%, 10%, and 12% Tris Acetate, Expedeon, San Diego, CA, USA) and resolved according to
the manufacturer’s operating guidelines. With each run, 12 fractions were collected as 150 µL aliquots.
Together with non-fractionated Vn96 proteome pellets, a 7 µL portion of each collected GELFrEE
fraction was subject to SDS-PAGE and silver staining, for visualization of mass-based separation and
recovery per fraction.
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Bottom up proteomic analysis of the GELFrEE-fractionated proteome first proceeded via SDS
removal through chloroform–methanol–water precipitation, as described previously [25]. The resulting
protein pellet was resolubilized in 20 µL of 8 M urea, then diluted to a final volume of 100 µL in 50 mM
Tris buffer (pH 8). Proteins were reduced following addition of 5 µL of 200 mM DTT (30 min, 55 ◦C),
then alkylated by adding 10 µL 200 mM iodoacetamide (30 min, room temperature, dark). Proteins
were digested overnight at 37 ◦C following addition of 1 µg trypsin per fraction, and the reaction was
terminated with 10 µL of 10% TFA.
Mass spectrometry was on an LTQ classic linear ion trap (ThermoFisher, San Jose, CA, USA),
coupled to an Agilent 1200 HPLC system. Digested protein fractions were desalted by offline reversed
phase HPLC with UV detection [26], loading one-third of the total volume of purified protein onto
a 75 µm × 30 cm self-packed C12 column (3 µm Jupiter beads, Phenomenex, Torrance, CA, USA).
Peptides were separated using a 1 h linear solvent gradient from 5% acetonitrile/water/0.1% formic
acid to 35% acetonitrile/water/0.1% formic acid at flow rate of 0.25 µL/min. The LTQ operated in
data dependent mode (MS followed by zoom scan and tandem MS of the top three ions), with 30 s
dynamic exclusion over a mass range covering the full isotopic distribution of the peptide.
Peptide identification used the Thermo Proteome Discoverer (v. 1.3, ThermoFisher, Mississauga,
Canada) software package and the SEQUEST searching algorithm. MS spectra were searched
against the human UniProt database, at a mass tolerance of 1 Da, allowing static cysteine
carbamidomethylation and dynamic oxidation of methionine, and up to two missed cleavages per
peptide. A peptide false discovery rate of 1% by decoy database searching, and minimum of one
unique peptide per protein were employed for data filtering. Relative protein abundance was obtained
via spectral counting [27] with normalized peptide spectral matches (PSMs), obtained by way of a
ratio of the total number of PSMs observed in the SKBR3 cell line (highest PSM total) to that of the total
PSMs from the given cell line. Functional annotation was performed by Ingenuity Pathway Analysis
(QIAGEN Bioinformatics, Redwood City, CA, USA).
3. Results and Discussion
We report a comparative proteome investigation on an in vitro model of breast cancer, examining
the extracellular media from SKBR-3 (invasive cancerous cell), MCF-7 (non-invasive), and MCF-10a
(immortal but non-cancerous cells). While cells adapted to grow in plastic flasks are regarded as very
different from those obtained in vivo, material secreted by cancer cells into the external environment
in vitro is likely to produce a similar proteomic profile, reflecting the original growth from which it
was derived [28]. The Vn96 peptide was employed to selectively capture EV material released by
cultured cell lines into their growth media. Vn96 targets heat shock proteins (HSPs), overexpressed on
the surface of aggressive cancer cells, and by extension, their derivative vesicles [29]. The Vn96 peptide
has been shown to capture exosome-like vesicles containing proteins comparable to EV preparations
by traditional ultracentrifugation when analyzed by Western blot [21].
To demonstrate the specificity of Vn96 to pellet EVmaterial, exosomes from SKBR3were harvested
through conventional ultracentrifugation with separation into characteristic flotation zones by sucrose
density fractionation. As shown in Figure 1, the exosomal marker proteins TSG101 and Alix were
isolated in the fractions from 1.15 to 1.23 g/mL. Moreover, while these marker proteins remain
suspended in the supernatant (SN) following low speed centrifugation, the addition of Vn96 resulted
in recovery of exosomal markers in the pellet (P) of the low speed spin. These observations demonstrate
the capacity of Vn96 to concentrate proteins associated with vesicular material.
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Figure 1. Western blot analysis of fractions recovered from sucrose density gradient iso
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Figure 1. Western blot analysis of fractions recovered from sucrose density gradient isolation of SKBR3
extracellular vesicles (EVs) reveals the presence of exosomal marker proteins TSG101 (A) and Alix (B).
These proteins remain in the supernatant in the control sample following low speed centrifugation.
With addition of Vn96, the low speed spin recovers the same proteins in the pelleted material.
The Vn96 peptide was next employed to directly recover EV materials from filtered bioreactor cell
culture media. When observed by TEM Figure 2, material pulled down by Vn96 generally consisted of
bilayer orb structures between 30 and 50 nm in diameter, with electron dense centers. Such features
were also evident in the MCF-10a cell line, indicative that HSP-decorated vesicles are also released
by these cells. In recent years, the term “small EVs” has been used as an alternative to exosomes [30].
Vn96 may capture a subset of small EVs, as defined by surface accessorization of HSPs.
ȃ Ȅ
 
Figure 2. TEM images showing the distribution of microvesicular bodies recovered from
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Figure 2. TEM images showing the distribution of microvesicular bodies recovered from the
extracellular media by precipitation with Vn96 peptide of (A) SKBR3; (B) MCF-7; (C) MCF-10a. The size
distribution of the particles is consistent with small extracellular vesicles.
Electrophoretic profiling of Vn96 pull-downs yielded robust total protein profiles
(e.g., from SKBR3, Figure 3A lane 1). Replacement of Vn96 with a random peptide (SW) yielded
faint profiles likely to be aggregates of albumin and immunoglobulin from culture medium (Figure 3A,
lane 2). The heat shock proteins (HSP70, HSP90) targeted by Vn96 were depleted from the medium
and exclusively recovered in the low centrifuge speed pellet. Employing a random peptide (SW),
or scrambled amino acid sequence of Vn96 did not pellet these proteins (Figure 3B). Western blots
of EV material also identified PKM2, receptor kinase HER2, membrane protein TRPV6, and fatty
acid synthase; none of which were recovered using the null peptide (Figure 3B). The stability of
EVs isolated by Vn96 from SKBR3 is also evident in Figure 3C, which employs various commercial
detergent washes (components of Millipore’s subcellular proteome extraction kit, S-PEK). As seen
in lanes 1 and 2 of Figure 3C, neither cytosolic Extraction Buffer I (EB1), which contains the mild
detergent digitonin, nor membrane and organelle Extraction Buffer II (EB2), containing Triton X-100,
would solubilize the EV marker proteins from the Vn96 pellet. Similar results are obtained from the
other cell lines. Though EV marker proteins are retained following EB1 and EB2 washes, weakly
associated proteins are liberated from the EV pellet by these buffers (see Supplementary Figure S1).
These findings permit incorporation of stringent washes to further purify the EV fraction recovered
Proteomes 2017, 5, 25 6 of 16
in the Vn96 pellet. Immunoblot analysis on material recovered from the non-transformed MCF-10a
cell culture media, as well as for MCF-7, with the breast cancer exosomal marker CD24 [31], illustrate
that some, but not all, CD24 is released into the supernatant following incubation of the pellet with
EB II (results not shown). Thus, we subsequently chose a PBS washing protocol, also under reducing
conditions (25 mM TCEP), to achieve a balance of yield and purity. To fully solubilize EV proteins
(lane 3 of Figure 3C), the pellet is boiled in SDS gel-loading buffer, supplemented with 4 M urea (USB).
As a consequence, MS analysis demands an SDS-compatible proteomics workflow.
 
’
Ȯ
Figure 3. Immunoblots probing for exosomal marker proteins in the Vn96 pellets isolated from SKBR3
cell culture media. (A) A random peptide (SW) precipitates few proteins from the extracellular media,
as evident from a total protein stain; (B) Marker proteins are observed in the immunoblots of the
Vn96 pulldown following solubilization in SDS-containing buffer (USB); (C) Extracting the Vn96 pellet
with mild detergent buffers, EB1 & EB2, from Millipore’s subcellular proteome extraction kit, S-PEK,
will not release proteins from the Vn96 pellet, permitting incorporation of a wash step to improve
purity. As controls, equivalent volumes of culture medium were processed by ultracentrifugation
(UCF), the pellet was resuspended in electrophoresis buffer and loaded directly (Lane 11).
Mass spectrometry detection followed GELFrEE fractionation of the solubilized EV proteomes.
GELFrEE enables recovery of proteins in an SDS-containing buffer, with separation according to
molecular weight. SDS depletion via organic solvent precipitation permits LC/MS of trypsin-digested
proteins. As demonstrated in Figure 4A, a higher abundance of EV proteins was recovered from the
SKBR3 and MCF-7 cell lines, relative to the non-cancerous MCF-10a, in support of the theory that
aggressive cancer cells will overexpress EV materials. The decreased abundance of proteins recovered
by Vn96 from the MCF-10a cell media may also reflect a lower number of Vn96 binding opportunities,
due to lack of surface expressed HSP/chaperones. Nonetheless, it is clear that a greater concentration
of proteins is recovered from the tumorigenic cell lines. GELFrEE resolved the proteins over a mass
range extending to ~100 kDa Figure 4B, isolating proteins in discrete fractions according to molecular
weight (Figure 4C). A detailed listing of the identified proteins and peptides from each of the three cell
lines are provided as supplementary files (Tables S1–S3).
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) SDS-PAGE of proteins recovered from Vn96 pellets reveal significantly 
Figure 4. (A) SDS-PAGE of proteins recovered from Vn96 pellets reveal significantly more proteins from
the cancerous cell lines SKBR3 and MCF-7 relative to the non-cancerous control MCF-10a; (B) GELFrEE
fractionation resolves proteins according to molecular weight. Shown is the separation of SKBR-3
proteins from the EV pellet as obtained on the 8% (highmolecular weight) gel cartridge; (C) Immunoblot
of the identically resolved proteome as above, showing resolution of heat shock proteins (HSP70
and HSP90).
As summarized in the Venn diagrams of Figure 5, some ~300 to 400 unique proteins were
identified from each cell type (minimum 2 peptides per protein). The largest number of identified
proteins (392) was seen from the most aggressive cancer cell line (SKBR3), and might be a reflection
of the increased prominence of HSPs expressed on the EV surface. Considering all three samples
and technical replicates (three GELFrEE runs per sample type), MS collectively identified 647 unique
proteins across the various cell lines. Despite marked differences in protein concentration across
the three cell lines, similar numbers of proteins were identified through MS. This may reflect on the
limitations of an MS platform which favors detection of the most abundant components. While greater
differences are reflected at the peptide level Figure 5, comparative analysis of the discrete proteomes is
best presented through changes in the protein abundance. Here, spectral counting is employed as a
means of assessing relative protein abundance across the three cell types. In total, we obtained 7400
peptide spectral matches (PSMs) from SKBR3; 4584 PSMs from MCF-7; and 2381 PSMs from MCF-10a,
being indicative of the greater concentration of EV proteins recovered in the most invasive phenotype.
Supplementary Table S4 details a full comparative assessment of the spectral matches observed per
protein across the three cell lines. Supplementary Table S5 compares the identified proteins to the
ExoCarta protein database [32], indicating that the majority of proteins detected (509 of 575 gene
products) were previously found to be associated with exosomal material.
Figure 5. Venn diagrams summarize (A) the proteins and (B) peptides identified by mass
spectrometry from each of the three cell lines. Detailed listings of identified proteins are provided as
supplemental files.
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Reflecting the origin of EVs as they are produced by the cell, and considering the cellular
distribution of proteins identified from the EV fractions (Supplementary Figure S2), it is not surprising
that several of the identified proteins were associated with the membrane (19%), or cellular surface
(12%). The large number of extracellular proteins is reflective of the heat shock proteins along with
other proteins normally released by cells. Tables 1–3 summarize the top 25 proteins (excluding probable
contaminants), as categorized according to primary function (metabolism; chaperone and protein
binding; skeletal and assembly).
Table 1. Top 25 proteins identified in SKBR3 EV fraction, excluding probable contaminants.
SKBR3
Protein Name ID Unique Peptides PSMs Function
Enolase P06733 13 197 metabolism
Fatty acid synthase P49327 20 139 metabolism
Phosphoglycerate kinase P00558 11 82 metabolism
Fructose bisphosphatase 1 P09467 11 70 metabolism
GAPDH E7EUT5 7 64 metabolism
Malate dehydrogenase E9PDB2 10 59 metabolism
L-lactate dehydrogenase P00338 8 50 metabolism
Aldehyde dehydrogenase F8W0A9 8 48 metabolism
Aldolase H3BPS8 6 33 metabolism
Triosephosphate isomerase P60174 6 31 metabolism
Glucosidase 2 subunit beta P14314 6 28 metabolism
Selenium-binding protein 1 Q13228 6 106 binding
60 kDa heat shock protein P10809 8 101 binding
Protein disulfide-isomerase I3L2P8 9 63 binding
14-3-3 protein zeta/delta P63104 6 49 binding
Lamin A/C Q6UYC3 6 49 binding
Tumor protein D52 D3YTI0 7 44 binding
14-3-3 protein epsilon P62258 8 38 binding
TER ATPase P55072 6 25 binding
Cytokeratin 19 P08727 18 635 assembly
Cytokeratin 8 P05787 20 350 assembly
Cytokeratin 18 F8VZY9 8 112 assembly
Cytokeratin 16 P08779 7 109 assembly
alpha-Actinin-4 O43707 11 72 assembly
Myosin-9 P35579 11 26 assembly
Table 2. Top 25 proteins identified in MCF-7 EV fraction, excluding probable contaminants.
MCF-7
Protein Name ID Unique Peptides PSMs Function
Enolase P06733 9 103 metabolism
Aldolase H3BQN4 7 62 metabolism
Fructose bisphosphatase 1 P09467 11 59 metabolism
Triosephosphate isomerase P60174 8 49 metabolism
Pyruvate kinase P14618 7 45 metabolism
Phosphoglycerate kinase B7Z7A9 8 38 metabolism
GAPDH E7EUT5 6 27 metabolism
Tryptophan-tRNA ligase P23381 8 23 metabolism
Cathepsin D P07339 5 20 metabolism
Kynureninase Q16719 6 15 metabolism
TER ATPase P55072 5 15 metabolism
Lactoferroxin-C B7Z4X2 9 14 metabolism
Hexokinase-1 B4DG62 7 13 metabolism
14-3-3 protein zeta/delta P63104 7 83 binding
14-3-3 protein epsilon P62258 9 63 binding
Selenium-binding protein 1 Q13228 6 38 binding
HSP 90-a P07900 5 29 binding
Agrin O00468 5 25 binding
Protein SET Q01105 5 21 binding
Cytokeratin 8 P05787 23 557 assembly
Cytokeratin 19 P08727 11 241 assembly
Cytokeratin 18 P05783 13 197 assembly
Actin, cytoplasmic 1 P60709 9 103 assembly
Filamin A A6NDY9 7 38 assembly
Lamin A/C Q6UYC3 6 38 assembly
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Table 3. Top 25 proteins identified in MCF-10a EV fraction, excluding probable contaminants.
MCF-10a
Protein Name ID Unique Peptides PSMs Function
Enolase P06733 5 29 metabolism
GAPDH E7EUT5 4 15 metabolism
Matrix metalloproteinase-2 B4DWH3 4 7 metabolism
Tripeptidyl-peptidase 1 O14773 3 7 metabolism
Cathepsin D P07339 3 5 metabolism
Complement component 1r H0YFH3 3 4 metabolism
Protein disulfide-isomerase P13667 3 4 metabolism
Anastellin F8W7G7 12 63 binding
Periostin F5H628 4 29 binding
Serpin B5 P36952 4 15 binding
TGF-β-induced protein ig-h3 G8JLA8 6 14 binding
Actin, cytoplasmic 1 F5GYT4 4 70 assembly
Laminin subunit gamma-2 F5H430 4 53 assembly
Filamin A A6NDY9 6 39 assembly
Cytokeratin 8 P05787 4 31 assembly
Alpha-actinin-4 O43707 6 23 assembly
Thrombospondin-1 P07996 5 20 assembly
Laminin subunit gamma-1 P11047 3 16 assembly
alpha-Actinin-1 H9KV75 5 13 assembly
Myosin-9 P35579 4 13 assembly
Tropomyosin a-1 chain H0YKP3 3 10 assembly
Agrin O00468 5 9 assembly
Filamin-B O75369 4 7 assembly
Desmoplakin P15924 3 4 assembly
Laminin subunit alpha-5 O15230 3 4 assembly
Multiple cytoskeleton proteins (keratins, actin, myosin, etc.) dominated the list of identified
proteins (see Supplementary Tables S1–S3). Keratins are frequently encountered as unavoidable
contaminant proteins during sample collection and processing. As such, suspected keratin
contaminants (keratin type 1, 2, 5, 9, 14, 16) were among the identified proteins. These proteins
exhibit minimal statistical difference in peptide spectral counts among the three cell types. However,
such contaminants are easily distinguishable from bona fide cancer markers, such as cytokeratin 8,
18, and 19. These molecules are found at the surface of cancer cells, and are thus either incorporated
as bystanders, or as part of the EV assembly and embarkation process. CK8 and CK18 are well
documented as secreted cancer biomarkers, and may be detected in serum of patients with breast
cancer receiving chemotherapy [33]. Thesemarkers were shown to resist extraction bywash buffers EB1
and EB2 (Supplementary Figure S1), and are thus likely to be strongly associated or embedded within
the extracellular vesicles. CK19 has been suggested to be likely involved in driving the more aggressive
tumor proliferation, invasion, andmetastasis associated with HER-2/neu-positive tumors [34]. By their
PSMs, each of these marker proteins were highly elevated in the cancer cell lines relative to MCF-10a
(Tables 1–3). Thus, these proteins are included in the lists of relevant EV components.
Considering the full list of proteins collectively identified in the EV material, a broad range of
biological function is conveyed (Supplementary Figure S2). The largest group of proteins identified
(18%) were associated with metabolic activity. The chaperone/binding proteins were also prominent
among the identified groups. A preliminary comparison of the molecular pathways associated with the
identified proteins is seen through Ingenuity Pathway Analysis (IPA), for which the top 12 pathways
of each cell type are depicted in Supplementary Figure S3. The most distinguishing feature was
the glycolysis/gluconeogenesis and the pentose phosphate pathways, represented at the top of IPA
pathways represented in SKBR3 (second and fourth for MCF-7). By sharp contrast, metabolic enzymes
constitutive of these pathways were essentially absent from MCF-10a.
Cancers are dominated by metabolic pathways that vary from normative physiology with
emphasis on accelerated uptake of glucose and glutamine, aerobic glycolysis, decreased mitochondrial
activity, and enhanced lipogenesis. Table 4 provides a quantitative comparison of proteins involved
in metabolic pathways. Perhaps the most well-known characteristic, the Warburg effect [35], refers
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to the avid consumption of glucose for direction into a glycolytic pathway with the accumulation
of lactate, rather than incorporation of pyruvate into the tricarboxylic acid (TCA) cycle for oxidative
phosphorylation. Nine of the ten canonical enzymes of glycolysis were represented in the Vn96
captured EVs of both SKBR3 and MCF-7, though only five were observed in MCF-10a. Some elements
were exclusively found in the invasive and non-invasive VNEs, such as isoforms of pyruvate kinase
and lactate dehydrogenase. Lactate dehydrogenase is perhaps the most widely recognized secreted
enzyme of glycolysis contributing to the acidification paradigm of the Warburg effect [36]. Metabolism
is thus closely linked to cancer progression, because the ability for a cell to proliferate is dependent
upon the availability of nutrients to build new cells. Glycolytic enzymes also protect cancer cells from
stress by inhibiting apoptosis, and correlate well with resistance to radio- and chemotherapy [37,38].
Early diversions are promoted toward the pentose phosphate pathway as the means to generate
nucleotide and amino acids. Of relevance was the detection of phosphogluconate dehydrogenase in
higher abundance for the cancerous cell lines.
Table 4. Summary of proteins involved in metabolic pathways and detected in EV pellets for each
cell lines.
Protein Description Process
Protein Spectral Hits (PSMs)
SKBR3 MCF7 MCF10
Hexokinase 1 Glycolysis/Gneo 1 13 0
Glucose-6-phosphate isomerase Glycolysis/Gneo 1 1 0
Phosphofructokinase Glycolysis/Gneo 0 0 0
Aldolase (fructose 1,6-bisphosphatase) Glycolysis/Gneo 138 176 12
Triosephosphate isomerase 1 Glycolysis/Gneo 31 49 2
GAPDH Glycolysis/Gneo 64 27 15
Phosphoglycerate kinase Glycolysis/Gneo 82 38 5
Phosphoglycerate mutase Glycolysis/Gneo 7 3 0
Enolase Glycolysis/Gneo 197 123 29
Pyruvate kinase Glycolysis/Gneo 17 45 0
Fatty Acid Synthase Lipogenesis 139 1 0
Tumor Protein D52 Lipid storage 44 0 0
Lactate dehydrogenase A Glycolysis/Gneo 50 40 0
Lactate dehydrogenase B Glycolysis/Gneo 11 0 0
6-phosphogluconate dehydrogenase Pentose Phosphate 27 22 7
Isocitrate dehydrogenase TCA 29 14 0
Beyond glycolysis, the provision of raw materials into peripheral biosynthetic pathways is crucial
to cancer survival and colonization of areas distal to the primary tumor [39]. For example, glycolysis
channels raw material into lipid biosynthesis for membrane expansion and vesicle production [40,41].
Lipogenesis, required for membrane expansion and vesicle production, and typical of the aggressive
cancer, would benefit from the donation of precursors. As seen in Table 4, a high proportion of peptides
originate from fatty acid synthase (FASN) in the invasive SKBR3. Similarly, tumor protein D52 was
also exclusively observed in SKBR3, being implicated in increased capacity for storing lipid typical
of invasive cancer cells [42]. The significance of FASN abundance in an invasive phenotype is likely
associated with the promotion of membrane biogenesis. FASN is frequently associated with invasive
cancer, and has been proposed as a therapeutic target [43]. It is normally expressed in low levels
when dietary sources are sufficient. However, FASN expression and activity in cancer cells can be
very high, and becomes associated with lipid rafts following cell signaling events [44]. Serum levels
of FASN have been found extracellularly in breast cancer [45], and are predictive of colorectal cancer
stage [46]. FASN has previously been found in exosomes from multiple cancer cells [32]. Accordingly,
it is possible that proportional representation of FASN in exosomes is a prospective biomarker of
invasive phenotype [47].
As ligands for the Vn96 affinity peptide, individual canonical heat shock proteins are listed
in Table 5. HSP60 was the most abundantly represented heat shock protein among the three cell
lines, and most highly expressed in SKBR3. HSP60 is a known surface-displayed molecule, secreted
by cancer cells, and an important marker of cancer-derived exosomes [48]. Isoforms of HSP90
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were more extensively represented in SKBR3, though also observed in the non-cancerous cell line
MCF7. HSP90-alpha constitutes the extracellular isoform, and is particularly characteristic of invasive
cancer [49]. Although location of HSP90 isoforms was not determined, this family of proteins is
frequently found on the cell surface of cancer cells, and by extension, on derivative vesicles [50]. HSP90
is imperative as a stabilizing chaperone of a broad range of aberrantly overactive receptors and kinases
imperative to cancer. Transient HSP–multi protein complexes, coined as the “epichaperome” and
found in high prevalence on numerous cancers, have been shown to play important roles in facilitating
cell regulation and survival [51]. Thus, while smaller chaperones, HSP10 or HSP27, were observed
in higher abundance in the cancerous cell lines, it is unknown if these are independently capable of
engaging Vn96. However, HSP10 and 27 have been implicated in multifunctional chaperone networks
in invasive breast cancer [52]. HSP chaperone complexes not only present biomarkers for cancer
diagnostics, but have been identified as targets for drug therapy [51].
Table 5. Canonical heat shock proteins identified in the EV fractions.
Protein Name SwissProt Accession Number
Peptide Spectral Matches
SKBR3 MCF7 MCF10a
HSP10 [B8ZZL8] 7 7 0
HSP60 [P10809] 101 9 0
HSP70-1A/1B [P08107] 3 7 1
HSP71 [E9PKE3], [E9PQQ4] 0 5 2
HSP27 [P04792], [B4DL87] 32 53 4
GRP78 (Hsp70-5) P11021 57 16 0
HSP90-alpha [P07900] 77 29 39
HSP90-beta [P08238] 70 0 41
GRP94 (Hsp90-B1) [P14625], [E9PEX3] 12 4 6
SUM: 347 126 87
The functional elements of a metastatic cascade reside in secreted proteins invested in
HSP-decorated EVs. Cumulatively, these proteins enable cells to detach, invade tissue, and access
circulation, while buffering against toxicity. Proteome profiling of the EV materials from malignant
vs non-invasive phenotypes reveals multiple features conducive to malignancy, some of which have
only been appreciated in the last year. A short selection is provided in Table 6. The role of these
proteins in cancer progression is described in the table with reference to literature. For example, protein
disulfide isomerases are multifunctional chaperones instrumental in the breakage and rearrangement
of disulfide bonds of extracellular matrix proteins, being required for detachment, extravasation,
and intravasation at secondary sites, particularly with regard to cellular matrix remodeling. Other
proteins may protect or preserve aspects crucial to metabolism (e.g., selenium-binding protein 1),
while other proteins may promote expression of specific proteins or enable function to maintain the
malignant phenotype (14-3-3 zeta). The Vn96 protocol to isolate EV materials uncovers multiple
distinguishing protein features, which collectively constitute candidate biomarkers of breast cancer.
Table 6. Selected EV pulldown proteins conducive to malignancy, listing peptide spectral matches.
Protein Description Accession SKBR3 MCF7 MCF10 Function Ref.
Selenium-binding protein 1 [Q13228] 106 38 0 Detox [53]
PDIA1 (P4HB) [I3L2P8] 63 0 0 Invasion [54]
PDIA3 (ERP57, GRP58) [H7BZJ3] 52 6 1 Invasion [55]
Aldehyde dehydrogenase 1 [F8W0A9] 48 0 0 Detox [56]
14-3-3 zeta/delta ζ [P63104] 49 82 0 Enabler [57]
Sushi Domain Containing D2 [Q9UGT4] 48 0 0 Invasion [58]
Acylamino-acid-releasing [P13798] 41 14 0 Detox [59]
Calcyphosin [Q13938] 41 0 0 Proliferation [60]
SS DNA-binding [Q04837] 38 0 0 Resistance [61]
Galectin-3-binding [Q08380] 36 0 0 Invasion [62]
Calreticulin [P27797] 33 0 0 Protection [63]
60S ribosomal P2 [P05387] 31 0 0 Enabler [64]
Glucosidase 2 beta (80-KH) [P14314] 28 2 7 Invasion [65]
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Previous investigations on breast cancer cell lines [66], or of their secreted exosomes [67],
have highlighted proteomic profiles indicative of cancer cell proliferation and mobility, which was also
apparent from our study. Our observations also corroborate a proteomic study that identified proteins
involved in metabolic and detoxification pathways as highly expressed in HER-2/neu-positive breast
cancer [68].
4. Conclusions
Vesicles were recovered from extracellular media by peptides with affinity to heat shock proteins,
which are abundant on cancer cell surface and derivative vesicles or exosomes. Extracellular
vesicles (EVs) were subject to GELFrEE fractionation and proteome analysis via bottom up liquid
chromatography mass spectrometry (LC/MS). Enzymes typical of altered metabolic pathways were
abundantly represented in EVs from cancer cells. Vesicle-associated proteins from the most invasive
phenotype, SKBR3, included most of the canonical enzymes of glycolysis and gluconeogenesis.
In contrast, the same proteins were of limited representation or absent in EVs from non-transformed
MCF-10a, while MCF-7 yielded an intermediate representation. These observations indicate that the
collection of extracellular vesicles from different cancer cell phenotypes may provide insight into the
importance of individual enzymes in cancer progression, and further, that the vesicles shed from
cancer cells serve as surrogates for profiling abundance of altered metabolic enzymes.
Supplementary Materials: The following are available online at www.mdpi.com/2227-7382/5/4/25/s1,
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